Cocrystal Pharma Selects Lead Compound for Further Development Against Coronaviruses
December 22, 2020 08:30 ET
|
Cocrystal Pharma, Inc.
CDI-45205 holds potential as a therapeutic and as a prophylactic to protect against coronavirus transmission, including SARS-CoV-2 BOTHELL, Wash., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cocrystal...